pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 23·1 min read
save

Podcast explores father's quest for ultra‑rare disease therapy, telehealth GLP‑1 prescribing probe and fugitive posing as biotech exec

Jul 23, 2026·read at STAT ↗Neutral

The latest episode of STAT’s "The Readout Loud" podcast examines three distinct stories that intersect with the biotech world. Hosts Allison DeAngelis and Elaine Chen sit down with colleagues Jason Mast and Matthew Herper, and invite guest Matt Wilsey, to discuss the topics in depth.

One segment follows Matt Wilsey, a father who is driving the development of a treatment for his daughter’s ultra‑rare disease. The conversation explores the scientific and logistical hurdles involved in creating a therapy for a condition that affects very few patients.

The episode also reviews STAT’s investigation into LifeMD, a telehealth provider that partners with Novo Nordisk. The report raises concerns about the company’s prescribing practices for GLP‑1 weight‑loss drugs, suggesting potential overuse or inappropriate prescriptions.

Finally, the hosts touch on a separate allegation that a wanted fugitive has been masquerading as a biotech executive, adding a layer of intrigue to the broader discussion of industry integrity.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing”

read at STAT ↗
514 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO5Ultragenyx Pharmaceutical Inc.5LILLY4Novo Nordisk Inc4ELI LILLY CO3Eli Lilly and Co
drugs
Obesity4Rare Disease4
topics
Rare Disease5Obesity4GLP-1 receptor3

related stories

  • 5d agoShould amylin have been obesity therapeutics’ primary target from the start?BioSpace
  • Sep 23Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • Sep 22Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectationsBioSpace
  • Aug 28Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist MounjaroBioSpace
  • Oct 8Eli Lilly and the LA Dodgers: A tale of 2 dynastiesBioSpace